Ellen Weisberg

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Molecular Pharmacology, Mutant Bcr-abl, Medicine +5

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Ellen Weisberg, Christina Boulton, Louise Kelly et al. · Cancer Cell · 2002 · 596 citations · Full text

Hematological Malignancy, Signal Transduction, Signaling Pathway +9

Smad4 and FAST-1 in the assembly of activin-responsive factor

Xin Chen, Ellen Weisberg, Valérie Fridmacher et al. · Nature · 1997 · 568 citations

Protein Function, Molecular Physiology, Signal Transduction +6

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Hai‐Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk et al. · Cell chemical biology · 2017 · 431 citations · Full text

Protein Function, Chemoproteomic Approach, Structural Bioinformatics +13

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines

Ellen Weisberg, James D. Griffin · Blood · 2000 · 399 citations